Pfizer's Metsera Acquisition Opens Opportunities in Obesity Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2026
0mins
Source: NASDAQ.COM
- Acquisition Strategy: Pfizer's acquisition of Metsera last year, valued at approximately $7 billion, while modest compared to its $43 billion Seagen purchase in 2023, demonstrates its ambition in the obesity market, potentially laying the groundwork for future growth.
- R&D Plans: The company aims to advance 10 phase 3 clinical trials in 2023, targeting its first approval by 2028, focusing on developing ultra-long-acting peptides, which, if successful, could provide a competitive edge by offering a monthly maintenance dosing option.
- Market Positioning: Although Pfizer's GLP-1 drugs are not yet approved, the company remains optimistic about its future potential in the obesity market, with CEO Albert Bourla emphasizing the need to maximize the value of the Metsera acquisition to establish leadership in next-generation obesity therapies.
- Investment Safety: Compared to smaller pre-revenue biotech firms, Pfizer, as a large and established healthcare giant, presents a lower investment risk, with its stock trading at only eight times its estimated future earnings, indicating potential upside in the GLP-1 market while mitigating downside risks for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 23.720
Low
24.00
Averages
28.56
High
35.00
Current: 23.720
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dividend Investment Opportunities in Pfizer and Bristol Myers Squibb
- Pfizer's Market Performance: Pfizer became the first biopharmaceutical company to surpass $100 billion in annual sales in 2022, but has lagged behind broader equities due to declining COVID-19 product revenues and impending patent cliffs, with a potential transformation in the next five years through its rich pipeline.
- Pipeline Potential: Pfizer's oncology drug PF'4404 is currently in phase 3 trials and is expected to deliver significant clinical wins, while its weight loss pipeline is also progressing steadily; despite poor financial results, some products are expected to drive sales growth.
- Bristol Myers' Recovery: After facing patent cliffs, Bristol Myers' revenue is slowly rebounding, and while it faces more patent expirations, the approval of a new subcutaneous version of Opdivo is expected to contribute to revenue growth in the coming years.
- Collaboration and Innovation: Bristol Myers is partnering with Johnson & Johnson to develop the next-gen anticoagulant Milvexian, which has received FDA Fast Track designation, indicating strong market potential, while also working on bispecific antibodies, with significant progress expected in the coming years.
See More
Pfizer's Dividend Risks Heighten Amid Challenges
- Attractive Dividend Yield: Pfizer's current dividend yield stands at 7%, which, while enticing to investors, may indicate deeper issues as the stock has plummeted 60% from its 2022 peak, reflecting market concerns about future performance.
- Earnings and Payout Ratio: With an estimated earnings per share of $2.99 for 2023 and a dividend payout of $1.72, Pfizer's payout ratio appears healthy at 57%; however, projected cash flow shortfalls in 2025 raise red flags about its ability to sustain dividends.
- Patent Cliff Risks: Pfizer is approaching a patent cliff that could result in a $17 billion revenue loss by 2030, particularly with the expiration of its top-selling drug Eliquis in 2025, posing significant financial challenges ahead.
- Tight Cash Flow: Although Pfizer has $13 billion in cash reserves, the uncertainty surrounding future cash flows and the inability to cover dividends could undermine investor confidence in the sustainability of its dividend payments.
See More
High Dividend Stock Analysis: Verizon Leads
- High Dividend Overview: Among the S&P 500, Verizon, General Mills, Pfizer, and Kraft Heinz all boast dividend yields exceeding 6%, with Pfizer leading at 7.20%, highlighting its attractiveness and potential investment value.
- Payout Ratio Analysis: Pfizer's payout ratio of 56.2% is the lowest, indicating its ability to maintain high dividends while retaining sufficient funds for growth investments, making it more sustainable compared to Verizon's 57.6% and General Mills' 68.7%.
- Dividend Growth History: Verizon has raised its dividend for 21 consecutive years, demonstrating strong financial strength and long-term commitment, while Pfizer has maintained growth for 15 years, providing investor confidence in their dividend stability.
- Investment Return Performance: Despite General Mills' 20% decline year-to-date, Verizon has achieved a 4% annualized return over the past three years, and analysts generally favor its future prospects, with 41% rating it a buy and a target price of $50.50, indicating a 22% upside.
See More
Pfizer Eyes Kailera Acquisition to Expand Weight Loss Portfolio
- Vaccine Dependency Decline: Pfizer has significantly underperformed over the past three years, primarily due to its reliance on COVID-19 vaccines, which have seen declining vaccination rates, putting pressure on sales and impacting overall market performance.
- Acquisition Potential: CEO Albert Bourla highlighted the company's 'very big balance sheet,' indicating its capability to pursue potential acquisitions in the future, despite having made several buyouts in recent years, reflecting a proactive approach to business expansion.
- Weight Loss Market Opportunity: Pfizer bolstered its weight loss portfolio by acquiring Metsera for up to $10 billion, with its lead asset MET-097i now in phase 3 trials, showcasing the company's strategic positioning in the rapidly growing anti-obesity market.
- Attractiveness of Kailera: Kailera Therapeutics' leading candidate ribupatide mimics the actions of two gut hormones, potentially offering a competitive edge in the weight loss market; acquiring Kailera would significantly enhance Pfizer's differentiated pipeline in this sector.
See More
Alnylam Pharmaceuticals Shares Drop 24%, Yet Optimism Persists
- Significant Revenue Growth: Alnylam Pharmaceuticals reported a 121% year-over-year surge in product revenue to $1.04 billion in Q1, primarily driven by a 153% increase in its ATTR franchise, indicating strong market demand in the rare disease treatment sector.
- Profitability Improvement: The company achieved earnings per share (EPS) of $1.51, a substantial turnaround from a loss of $0.14 per share in the same period last year, demonstrating Alnylam's rapid transition into a profitable commercial powerhouse, which boosts investor confidence.
- Expansion into New Indications: New data for Alnylam's Amvuttra reinforces its position as a first-line treatment for cardiomyopathy, setting the stage for a massive commercial launch and further market share expansion.
- Strong Technological Moat: Alnylam's RNA interference platform creates a deep technological moat, and its collaboration with Inceptive Nucleics on AI accelerates the discovery of next-generation RNAi structures, ensuring its competitive edge in the biotech industry.
See More
Alnylam Pharmaceuticals Reports Strong Q1 Performance
- Significant Revenue Growth: Alnylam Pharmaceuticals reported a 121% year-over-year surge in product revenue to $1.04 billion in Q1, primarily driven by a 153% increase in its transthyretin amyloidosis (ATTR) franchise, indicating strong market demand in the rare disease treatment sector.
- Profitability Improvement: The company achieved earnings per share (EPS) of $1.51, a substantial turnaround from a loss of $0.14 per share in the same period last year, marking a significant improvement in profitability and showcasing its transition from a high-burn clinical biotech to a profitable commercial powerhouse.
- Broad Market Outlook: Alnylam's guidance for full-year 2026 net product revenue ranges between $4.9 billion and $5.3 billion, reflecting a 71% year-over-year growth at the midpoint, highlighting the company's potential to penetrate mainstream high-volume therapeutic markets, particularly in cardiomyopathy and hypertension.
- Strong Technological Moat: Alnylam's RNA interference (RNAi) drug delivery system creates a deep technological moat, and its strategic AI collaboration with Inceptive Nucleics accelerates the discovery of next-generation RNAi structures, ensuring the company's competitive edge in the rapidly evolving biotech landscape.
See More
Dividend Investment Opportunities in Pfizer and Bristol Myers Squibb
- Pfizer's Market Performance: Pfizer became the first biopharmaceutical company to surpass $100 billion in annual sales in 2022, but has lagged behind broader equities due to declining COVID-19 product revenues and impending patent cliffs, with a potential transformation in the next five years through its rich pipeline.
- Pipeline Potential: Pfizer's oncology drug PF'4404 is currently in phase 3 trials and is expected to deliver significant clinical wins, while its weight loss pipeline is also progressing steadily; despite poor financial results, some products are expected to drive sales growth.
- Bristol Myers' Recovery: After facing patent cliffs, Bristol Myers' revenue is slowly rebounding, and while it faces more patent expirations, the approval of a new subcutaneous version of Opdivo is expected to contribute to revenue growth in the coming years.
- Collaboration and Innovation: Bristol Myers is partnering with Johnson & Johnson to develop the next-gen anticoagulant Milvexian, which has received FDA Fast Track designation, indicating strong market potential, while also working on bispecific antibodies, with significant progress expected in the coming years.
See More
Pfizer's Dividend Risks Heighten Amid Challenges
- Attractive Dividend Yield: Pfizer's current dividend yield stands at 7%, which, while enticing to investors, may indicate deeper issues as the stock has plummeted 60% from its 2022 peak, reflecting market concerns about future performance.
- Earnings and Payout Ratio: With an estimated earnings per share of $2.99 for 2023 and a dividend payout of $1.72, Pfizer's payout ratio appears healthy at 57%; however, projected cash flow shortfalls in 2025 raise red flags about its ability to sustain dividends.
- Patent Cliff Risks: Pfizer is approaching a patent cliff that could result in a $17 billion revenue loss by 2030, particularly with the expiration of its top-selling drug Eliquis in 2025, posing significant financial challenges ahead.
- Tight Cash Flow: Although Pfizer has $13 billion in cash reserves, the uncertainty surrounding future cash flows and the inability to cover dividends could undermine investor confidence in the sustainability of its dividend payments.
See More
High Dividend Stock Analysis: Verizon Leads
- High Dividend Overview: Among the S&P 500, Verizon, General Mills, Pfizer, and Kraft Heinz all boast dividend yields exceeding 6%, with Pfizer leading at 7.20%, highlighting its attractiveness and potential investment value.
- Payout Ratio Analysis: Pfizer's payout ratio of 56.2% is the lowest, indicating its ability to maintain high dividends while retaining sufficient funds for growth investments, making it more sustainable compared to Verizon's 57.6% and General Mills' 68.7%.
- Dividend Growth History: Verizon has raised its dividend for 21 consecutive years, demonstrating strong financial strength and long-term commitment, while Pfizer has maintained growth for 15 years, providing investor confidence in their dividend stability.
- Investment Return Performance: Despite General Mills' 20% decline year-to-date, Verizon has achieved a 4% annualized return over the past three years, and analysts generally favor its future prospects, with 41% rating it a buy and a target price of $50.50, indicating a 22% upside.
See More
Pfizer Eyes Kailera Acquisition to Expand Weight Loss Portfolio
- Vaccine Dependency Decline: Pfizer has significantly underperformed over the past three years, primarily due to its reliance on COVID-19 vaccines, which have seen declining vaccination rates, putting pressure on sales and impacting overall market performance.
- Acquisition Potential: CEO Albert Bourla highlighted the company's 'very big balance sheet,' indicating its capability to pursue potential acquisitions in the future, despite having made several buyouts in recent years, reflecting a proactive approach to business expansion.
- Weight Loss Market Opportunity: Pfizer bolstered its weight loss portfolio by acquiring Metsera for up to $10 billion, with its lead asset MET-097i now in phase 3 trials, showcasing the company's strategic positioning in the rapidly growing anti-obesity market.
- Attractiveness of Kailera: Kailera Therapeutics' leading candidate ribupatide mimics the actions of two gut hormones, potentially offering a competitive edge in the weight loss market; acquiring Kailera would significantly enhance Pfizer's differentiated pipeline in this sector.
See More
Alnylam Pharmaceuticals Shares Drop 24%, Yet Optimism Persists
- Significant Revenue Growth: Alnylam Pharmaceuticals reported a 121% year-over-year surge in product revenue to $1.04 billion in Q1, primarily driven by a 153% increase in its ATTR franchise, indicating strong market demand in the rare disease treatment sector.
- Profitability Improvement: The company achieved earnings per share (EPS) of $1.51, a substantial turnaround from a loss of $0.14 per share in the same period last year, demonstrating Alnylam's rapid transition into a profitable commercial powerhouse, which boosts investor confidence.
- Expansion into New Indications: New data for Alnylam's Amvuttra reinforces its position as a first-line treatment for cardiomyopathy, setting the stage for a massive commercial launch and further market share expansion.
- Strong Technological Moat: Alnylam's RNA interference platform creates a deep technological moat, and its collaboration with Inceptive Nucleics on AI accelerates the discovery of next-generation RNAi structures, ensuring its competitive edge in the biotech industry.
See More
Alnylam Pharmaceuticals Reports Strong Q1 Performance
- Significant Revenue Growth: Alnylam Pharmaceuticals reported a 121% year-over-year surge in product revenue to $1.04 billion in Q1, primarily driven by a 153% increase in its transthyretin amyloidosis (ATTR) franchise, indicating strong market demand in the rare disease treatment sector.
- Profitability Improvement: The company achieved earnings per share (EPS) of $1.51, a substantial turnaround from a loss of $0.14 per share in the same period last year, marking a significant improvement in profitability and showcasing its transition from a high-burn clinical biotech to a profitable commercial powerhouse.
- Broad Market Outlook: Alnylam's guidance for full-year 2026 net product revenue ranges between $4.9 billion and $5.3 billion, reflecting a 71% year-over-year growth at the midpoint, highlighting the company's potential to penetrate mainstream high-volume therapeutic markets, particularly in cardiomyopathy and hypertension.
- Strong Technological Moat: Alnylam's RNA interference (RNAi) drug delivery system creates a deep technological moat, and its strategic AI collaboration with Inceptive Nucleics accelerates the discovery of next-generation RNAi structures, ensuring the company's competitive edge in the rapidly evolving biotech landscape.
See More
